Creative Planning Buys 97,429 Shares of Organon & Co. $OGN

Creative Planning grew its stake in shares of Organon & Co. (NYSE:OGN) by 109.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,614 shares of the company’s stock after buying an additional 97,429 shares during the period. Creative Planning owned approximately 0.07% of Organon & Co. worth $1,806,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Organon & Co. by 22.4% in the 2nd quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock valued at $55,000 after acquiring an additional 1,034 shares during the period. Maryland State Retirement & Pension System grew its holdings in Organon & Co. by 1.4% during the second quarter. Maryland State Retirement & Pension System now owns 88,420 shares of the company’s stock valued at $856,000 after purchasing an additional 1,195 shares during the period. Allworth Financial LP increased its stake in Organon & Co. by 65.9% in the second quarter. Allworth Financial LP now owns 4,501 shares of the company’s stock valued at $44,000 after purchasing an additional 1,788 shares in the last quarter. Yousif Capital Management LLC raised its holdings in Organon & Co. by 2.3% in the second quarter. Yousif Capital Management LLC now owns 79,975 shares of the company’s stock worth $774,000 after purchasing an additional 1,789 shares during the period. Finally, Hantz Financial Services Inc. raised its holdings in Organon & Co. by 293.8% in the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after purchasing an additional 1,995 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Trading Up 3.5%

Shares of NYSE:OGN opened at $7.78 on Thursday. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 4.05, a PEG ratio of 1.61 and a beta of 0.59. Organon & Co. has a 12 month low of $6.18 and a 12 month high of $17.23. The company’s fifty day simple moving average is $8.71 and its 200 day simple moving average is $9.28. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69.

Organon & Co. (NYSE:OGN) last released its earnings results on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the prior year, the company earned $1.38 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Thursday, November 20th will be given a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, November 20th. Organon & Co.’s dividend payout ratio (DPR) is currently 4.17%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on OGN. Morgan Stanley decreased their price target on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 11th. JPMorgan Chase & Co. reduced their target price on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, November 11th. Piper Sandler cut Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price for the company. in a research note on Monday, October 27th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Organon & Co. currently has a consensus rating of “Hold” and an average target price of $12.50.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.